A research peptide nasal spray is a solution of known concentration in a metered-pump bottle, and its defining specification is not the peptide mass on the label but the mass delivered per actuation — concentration multiplied by the pump's fixed spray volume. Peptide nasal sprays exist in research because the nasal mucosa is thin, richly vascularised and directly adjacent to olfactory and trigeminal pathways, which makes it the standard non-parenteral route in intranasal delivery studies. This guide covers how these formulations are built, what limits which peptides can be sprayed, how to calculate per-actuation mass, and how liquid sprays behave in storage compared with lyophilized vials. All of it describes laboratory reference preparations supplied for research use only.
Why intranasal is studied at all
Peptides taken orally are degraded by gastric acid and by pancreatic and brush-border peptidases, and what survives faces hepatic first-pass metabolism; measured oral bioavailability for unmodified peptides is typically well under 1%, which is the problem discussed in oral peptides, capsules and troches. The nasal cavity offers roughly 150 cm² of thin, highly perfused epithelium with far less proteolytic activity and no portal drainage. Published intranasal work with small peptides has reported bioavailability figures ranging from a few percent to the low tens of percent depending on molecule and formulation — an enormous improvement over oral, still far below injection.
The second reason is anatomical. Rodent and non-human primate studies since the 1990s have reported that molecules deposited on the olfactory epithelium can reach cerebrospinal fluid and brain tissue along perineural spaces of the olfactory and trigeminal nerves, apparently bypassing the blood–brain barrier. That literature is why nootropic sequences dominate our nasal peptide sprays range — Semax, Selank and similar molecules are exactly the ones where a direct nose-to-brain route is the research question. The mechanism remains debated and the human evidence is thin; describe it as reported, not established.
What limits which peptides can be sprayed
- Molecular weight. Nasal absorption falls steeply above roughly 1,000 Da. Semax (813.93 Da) and Selank (751.89 Da) sit under that ceiling; a 4,113 Da GLP-1 analogue does not, which is why the sprayed formats in the catalogue skew small.
- Volume. The nasal cavity retains only about 100–150 µL before excess runs off, so a metered pump is built around a 0.1 mL actuation. Concentration, not volume, is the only lever for increasing delivered mass.
- Mucociliary clearance. Deposited material is swept toward the nasopharynx within roughly 15–20 minutes, capping residence time regardless of formulation.
- Chemical stability in water. A spray is an aqueous solution held at room temperature for weeks. Sequences containing methionine, cysteine or Asn-Gly motifs are the ones most likely to show oxidation, disulfide scrambling or deamidation over that window.
What is in a peptide nasal spray bottle
| Component | Typical role | Research note |
|---|---|---|
| Peptide | Active reference material | Mass stated on label; purity and identity on the lot COA |
| Buffered diluent | Holds pH near 5.5–6.5 | Nasal mucosa is mildly acidic; pH also affects peptide charge and stability |
| Tonicity agent (NaCl or mannitol) | Approximate isotonicity | Strongly hypo- or hypertonic solutions disturb ciliary function in tissue models |
| Preservative (benzalkonium chloride, benzyl alcohol) | Prevents microbial growth in a multi-actuation container | Preservative-sensitive assays need a preservative-free preparation instead |
| Metered pump, 15 mL bottle | Fixed 0.1 mL per actuation | The number that turns concentration into delivered mass |
Permeation enhancers — chitosan, cyclodextrins, bile-salt derivatives — appear throughout the intranasal literature and can raise measured absorption several-fold, but they also raise epithelial irritation in tissue models, so they belong in a formulation study rather than in a general-purpose research spray.
Worked example: from vial to per-actuation mass
Our nasal spray reconstitution kit supplies an empty 15 mL metered bottle plus buffered diluent, so the arithmetic is yours to set.
- Choose the concentration. A 10 mg peptide vial transferred into 10 mL of diluent gives 10 ÷ 10 = 1 mg/mL, i.e. 1,000 mcg/mL.
- Apply the pump volume. At 0.1 mL per actuation, each spray delivers 0.1 × 1,000 = 100 mcg.
- Count the actuations. 10 mL ÷ 0.1 mL = 100 theoretical actuations, less 3–5 lost to priming and 0.5–1 mL of unrecoverable residue below the dip tube. Plan on roughly 85–90 usable actuations, not 100.
- Change one variable. The same 10 mg vial in 5 mL gives 2 mg/mL and 200 mcg per actuation, with about 42 usable actuations. Halving the volume doubles delivered mass and halves the shelf life of the bottle in use.
The same mg/mL arithmetic used for injectable stocks applies here; the reconstitution calculator will run it if you enter the bottle volume in place of a vial diluent volume. If you would rather not assemble the components, the nasal spray DIY kit pairs a 10 mg Semax vial with the bottle and solution.
Verifying the pump rather than trusting it
Metered pumps are specified at 0.1 mL but individual units drift, and a pump that has not been primed delivers air or a partial volume for its first several strokes. The lab check is gravimetric: prime five times, then actuate ten times into a tared weighing boat and divide. Aqueous solutions are close enough to 1 g/mL that 1.0 g over ten actuations confirms 0.1 mL per stroke. Repeat when the bottle is roughly two-thirds empty, because delivered volume falls once the dip tube starts drawing air.
Storage and stability of the liquid format
A lyophilized vial is a dry solid and, kept frozen and dark, is stable for years. A spray is the opposite: an aqueous solution at room temperature with a septum-free opening. Every degradation route that matters for peptides — hydrolysis, deamidation, methionine oxidation, disulfide exchange, adsorption to the container wall — runs faster in solution.
- Store sealed, unopened sprays refrigerated at 2–8 °C and bring to room temperature before actuating; cold solution changes viscosity and the delivered volume with it.
- Once in use, refrigerated storage is still preferred. Preserved formulations tolerate room temperature but the peptide, not the preservative, is the limiting factor.
- Do not freeze an assembled spray. Ice formation concentrates solutes at the freeze front and can crack the pump body; freeze–thaw damage to peptide solutions is covered in how to store peptides.
- Keep bottles upright and out of light. Amber or opaque containers exist because tryptophan and tyrosine residues are photolabile.
- Treat an in-use bottle as having a working life of weeks, not months, and label it with the date it was made up. Vial labels and log sheets make that record part of the workflow rather than an afterthought.
Common mistakes
- Quoting the label mass as the delivered mass. A 10 mg bottle does not deliver 10 mg per actuation; it delivers concentration × 0.1 mL.
- Ignoring priming loss when calculating how many actuations a bottle provides.
- Reconstituting a spray with plain bacteriostatic water. It is sterile and preserved but unbuffered and hypotonic, so pH and tonicity are uncontrolled; buffered nasal diluent exists for that reason.
- Assuming a sprayable format for a large peptide. Above roughly 1,000 Da, absorption in published models drops far enough that a spray becomes a delivery study rather than a delivery method.
Further questions on formats, shelf life and shipping are collected in the nasal spray FAQ.